HONG KONG – November 03, 2026 -- WuXi Biologics (2269.HK) won two Grand Awards at the ninth Hong Kong ESG Reporting Awards (HERA), the only pharmaceutical company to do so among 120 entries.

The contract research, development and manufacturing organization (CRDMO) took Best ESG Report (Large-Cap) and Excellence in Environmental Positive Impact. HERA categories span ESG governance, environmental and social impact, carbon neutrality and workplace well-being. A panel drawn from academia, finance, sustainability advisory and regulatory backgrounds judges the program independently.

SBTi validated WuXi Biologics' emissions targets across Scope 1, 2 and 3 in 2025

The Science Based Targets initiative (SBTi) validated the company's near-term, long-term and net-zero greenhouse gas reduction targets in 2025. The targets cover Scope 1, 2 and 3 emissions and align with a 1.5°C pathway.

The company has also been named to the 2026 Forbes China ESG 50 list, cited for sustainable development, Green CRDMO solutions and ESG digital innovation.

CEO Chris Chen ties ESG disclosure to business resilience

Dr. Chris Chen, CEO and Chairman of the ESG Committee, said transparent ESG disclosure and strong environmental performance are integral to business resilience and long-term success. He said the company will continue advancing its ESG governance and Green CRDMO strategy with global partners across the value chain.

Project portfolio stands at 1,064 integrated client projects

As of June 30, 2026, WuXi Biologics supported 1,064 integrated client projects. Of these, 78 are in Phase III and 28 are in commercial manufacturing. Complex modalities account for more than half of the portfolio. The company employs more than 14,000 people across China, the United States, Ireland, Germany and Singapore.